99% OF PATIENTS GOT TO T GOAL BY DAY 7
FIRMAGON® T ≤50 ng/dL) ON DAY 11,2(degarelix for injection) HELPED 52% OF PATIENTS REACH CASTRATE LEVELS (
PERCENTAGE OFPATIENTS ACHIEVING CASTRATE LEVELS1*
The pivotal phase 3 trial (CS21) was a 3-armed, randomized (1:1:1), active-controlled, open-label, parallel-group, 12-month clinical study of FIRMAGON compared to leuprolide acetate (Lupron Depot®).3 Serum levels of testosterone were measured at screening, on days 0, 1, 3, 7, 14,and 28 in the first month, and then monthly until the end of the study.1
FIRMAGON was shown to maintain testosterone suppression below castration level (≤50 ng/dL) during 12 months of treatment.
- Proportion of patients with testosterone ≤50 ng/dL
- Serum levels of testosterone, prostate-specific antigen (PSA), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) over time
- Percentage change in PSA from baseline
Abbreviations: T = testosterone.
Lupron Depot is a registered trademark of ABBVIE ENDOCRINE INC.
Help make the most of your patient'streatment experience
Make the most of monthly visits. Help your patients feel connected to their therapy through the reassurance of regular treatment and progress check-ins. Ferring is here to help enhance this connection at every step.
REFERENCES: 1. FIRMAGON® [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 2. Data on file. Ferring Pharmaceuticals Inc. 3. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538.